Amivantamab-vmjw- (RYBREVANT)- (May 2021)- treat aduts with subset of non-small cell lung cancer

Drug Name:
Amivantamab-vmjw- (RYBREVANT)- (May 2021)- treat aduts with subset of non-small cell lung cancer

List Of Brands:

Indication Type Description:

Indication

Adverse Reaction

Contra-Indications

Dosages/ Overdosage Etc

Patient Information

Pharmacology/ Pharmacokinetics

Pregnancy and lactation